검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | 131-I Apamistamab |
Overview Company | Actinium Pharmaceuticals |
Overview Modality | ANTIBODY |
Overview Target | B-ALL |
Overview Indication | B-ALL; DLBCL |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | Of growing interest as therapeutic payloads are α-particle emitting radionuclides such as actinium-225 ( 225 Ac) or astatine-211 ( 211 At) since they deliver substantially higher decay energies over a much shorter distance than β-emitters, rendering them more suitable for precise, potent, and efficient target cell killing while minimizing toxicity to surrounding bystander cells, possibly allowing use outside of HCT. |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Randomized Phase III SIERRA Trial of 131 I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.. Older patients with relapsed or refractory AML (RR AML) have dismal prognoses without allogeneic hematopoietic cell transplantation (alloHCT). SIERRA compared a targeted pretransplant regimen involving the anti-CD45 radioconjugate 131 I-… |
Clinical Data Tier / Score | A · 9 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 6월 1일 (43일 전 · 갱신 권장) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | 131-I Apamistamab |
Overview Company | Actinium Pharmaceuticals |
Overview Modality | ANTIBODY |
Overview Target | B-ALL |
Overview Indication | B-ALL; DLBCL |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | Of growing interest as therapeutic payloads are α-particle emitting radionuclides such as actinium-225 ( 225 Ac) or astatine-211 ( 211 At) since they deliver substantially higher decay energies over a much shorter distance than β-emitters, rendering them more suitable for precise, potent, and efficient target cell killing while minimizing toxicity to surrounding bystander cells, possibly allowing use outside of HCT. |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Randomized Phase III SIERRA Trial of 131 I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.. Older patients with relapsed or refractory AML (RR AML) have dismal prognoses without allogeneic hematopoietic cell transplantation (alloHCT). SIERRA compared a targeted pretransplant regimen involving the anti-CD45 radioconjugate 131 I-… |
Clinical Data Tier / Score | A · 9 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 6월 1일 (43일 전 · 갱신 권장) |
추천 비교
추천 비교